e-learning
resources
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection
Benoît Bédat, Jérôme Plojoux, Jade Noel, Anna Morel, Jonathan Worley, Frédéric Triponez, Wolfram Karenovics
Source:
ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019
Journal Issue:
July
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Benoît Bédat, Jérôme Plojoux, Jade Noel, Anna Morel, Jonathan Worley, Frédéric Triponez, Wolfram Karenovics. Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection. ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients.
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018
An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection
Source: ERJ Open Res, 8 (1) 00590-2021; 10.1183/23120541.00590-2021
Year: 2022
Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019
Effectiveness and safety of tissue plasminogen activators (t-PA) in complicated pleural effusion (CPE), what the correlation with time it stays in the pleural space?
Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura
Year: 2013
A clinical comparison of intrapleural heparin versus urokinase in the management of tuberculous pleurisy
Source: Eur Respir J 2005; 26: Suppl. 49, 647s
Year: 2005
Intrapleural use of dornase alfa and tissue plasminogen activator are successful as treatment in pediatric empyema: a pilot study
Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes
Year: 2018
Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes
Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism
Year: 2017
Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells
Source: Eur Respir J 2007; 30: Suppl. 51, 143s
Year: 2007
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018
Year: 2019
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space
Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020
Year: 2020
Respiratory functional status after intrapleural t-PA administration for complicated parapneumonic effusions
Source: Annual Congress 2012 - Viral infections and rare respiratory infections
Year: 2012
Variable adoption of intrapleural fibrinolytic therapy for pleural space infections
Source: International Congress 2018 – Pleural interventions
Year: 2018
Efficacy of thrombolytic agents in the treatment of pulmonary embolism
Source: Eur Respir J 2005; 26: 864-874
Year: 2005
Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1
Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury
Year: 2009
Intrapleural urokinase in the management of empyema in children
Source: Eur Respir J 2004; 24: Suppl. 48, 620s
Year: 2004
Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model
Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2010
Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts
Source: Eur Respir J 2005; 26: Suppl. 49, 343s
Year: 2005
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
Source: Eur Respir J 2016; 47:1568-1571
Year: 2016
Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept